Web Results

www.justice.gov/archive/usao/pae/News/2009/sep/pfizer_settlementagreement.pdf

Pfizer, Inc. et al.,. Civ. No. 08-11318 (D. Mass.); United States ex rel. Robert A. Liter v. Pfizer,. Civ. No. 06-00176 (E.D. Ky); and. United States et al. ex rel. Stefan Kruszewski v. Pfizer, Inc,. Civ. No. 07-4106 (E.D. Pa.). C. On such date as may be determined by the Court, Pfizer subsidiary Pharmacia &. Upjohn Company, Inc.

www.crin.org/en/library/legal-database/rabi-abdullahi-v-pfizer-inc

Aug 8, 2016 ... UNITED STATES. Title: Rabi Abdullahi v Pfizer, Inc. Court: United States Court of Appeals for the Second Circuit. Citation: Docket Nos: 05-4863-cv (L), 05-6768-cv (CON). Date: 30 January 2009. Instrument(s) Cited: Alien Tort Statute, 28 U.S.C. § 1350. Connecticut Unfair Trade Practices Act Connecticut ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC5048367

Aug 17, 2016 ... But CSF NFL is also relevant in AD (Zetterberg et al, 2016) since AD not only involves loss of cortical structures but also white matter injury (Migliaccio et ... Specifically, we tested the hypotheses that (i) combinations of T‐tau, Ng, and NFL increase the diagnostic accuracy for AD versus controls (CN) and for ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC4039513

May 30, 2014 ... Objectives. To investigate whether APOE ε4 carriers have higher hippocampal atrophy rates than non-carriers in Alzheimer's disease (AD), mild cognitive impairment (MCI) and controls, and if so, whether higher hippocampal atrophy rates are still observed after adjusting for concurrent whole-brain atrophy ...